Drugs / ornithine alpha ketoglutarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00645879 | Jul 2008 → Aug 2009 | propionic acidemia | Nicola Longo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ornithine alpha ketoglutarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00645879 ↗ |
| Known as | ornithine α-ketoglutarate | “PURPOSE: The objective of this study was to determine whether supplements with glutamine (400mg/kg per day), citrate (7.5mEq/kg per day), or ornithine α-ketoglutarate (400mg/kg...” PMID 28712602 ↗ Jul 2017 |